These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 18177776)
1. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Tyrer P; Oliver-Africano PC; Ahmed Z; Bouras N; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; North B; Eliahoo J; Karatela S; Soni A; Crawford M Lancet; 2008 Jan; 371(9606):57-63. PubMed ID: 18177776 [TBL] [Abstract][Full Text] [Related]
2. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID). Tyrer P; Oliver-Africano P; Romeo R; Knapp M; Dickens S; Bouras N; Ahmed Z; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; Karatela S; Lenôtre L; Watson J; Soni A; Crawford M; Eliahoo J; North B Health Technol Assess; 2009 Apr; 13(21):iii-iv, ix-xi, 1-54. PubMed ID: 19397849 [TBL] [Abstract][Full Text] [Related]
3. The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis. Romeo R; Knapp M; Tyrer P; Crawford M; Oliver-Africano P J Intellect Disabil Res; 2009 Jul; 53(7):633-43. PubMed ID: 19460067 [TBL] [Abstract][Full Text] [Related]
4. Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Oliver-Africano P; Dickens S; Ahmed Z; Bouras N; Cooray S; Deb S; Knapp M; Hare M; Meade M; Reece B; Bhaumik S; Harley D; Piachaud J; Regan A; Ade Thomas D; Karatela S; Rao B; Dzendrowskyj T; Lenôtre L; Watson J; Tyrer P J Intellect Disabil Res; 2010 Jan; 54(1):17-25. PubMed ID: 19627427 [TBL] [Abstract][Full Text] [Related]
5. Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial. Deb S; Leeson V; Aimola L; Bodani M; Li L; Weaver T; Sharp D; Crawford M Trials; 2018 Jun; 19(1):325. PubMed ID: 29929537 [TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Loy JH; Merry SN; Hetrick SE; Stasiak K Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA; N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647 [TBL] [Abstract][Full Text] [Related]
9. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Sikich L; Hamer RM; Bashford RA; Sheitman BB; Lieberman JA Neuropsychopharmacology; 2004 Jan; 29(1):133-45. PubMed ID: 14583740 [TBL] [Abstract][Full Text] [Related]
10. Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. Amore M; Bertelli M; Villani D; Tamborini S; Rossi M J Intellect Disabil Res; 2011 Feb; 55(2):210-8. PubMed ID: 21129058 [TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
14. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G; Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797 [TBL] [Abstract][Full Text] [Related]
15. Aggressive behaviour in adults with intellectual disability: defining the role of drug treatment. Oliver-Africano P; Murphy D; Tyrer P CNS Drugs; 2009 Nov; 23(11):903-13. PubMed ID: 19845412 [TBL] [Abstract][Full Text] [Related]
17. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820 [TBL] [Abstract][Full Text] [Related]
18. Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol. Prescrire Int; 2009 Dec; 18(104):248. PubMed ID: 20025088 [TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121 [TBL] [Abstract][Full Text] [Related]
20. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]